Clinical trials: Invasive Carcinoma
Breast Cancer
Accuracy of FNA Versus CNB of Abnormal Axillary Lymph Nodes in Setting of Invasive Breast Cancer
To compare accuracy of ultrasound guided fine needle aspiration (FNA) to core needle biopsy (CNB) of ultrasound detected abnormal axillary lymph nodes in patients with newly diagnosed invasive breast cancer or suspected invasive…
- Trial name
- NCT02019303
- Testing
- FNA and Core biopsy
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- University of Utah
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
This pilot clinical trial studies stereotactic body radiation therapy after surgery in treating patients with stage III-IV non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT01781741
- Testing
- therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT), quality-of-life assessment
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Invasive Breast Carcinoma, Gynecologic Malignancies
Self-Acceptance and Supportive Accountability for Active Living Among Adults Receiving Chemotherapy
Physical activity can improve health-related quality of life among people receiving cancer treatment. Yet, chemotherapy imposes considerable barriers to maintaining an active lifestyle.
- Trial name
- NCT07819045
- Testing
- Acceptance- and Mindfulness-Based Intervention
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Oklahoma
Breast Cancer, Breast Cancer Female
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
The purpose of this study is to learn more about how to treat patients with HER-2/neu positive invasive breast cancer (IBC). HER-2/neu is a type of protein that is known to be over-expressed in aggressive breast cancer.
- Conditions
- Breast Cancer, Breast Cancer Female, Breast Cancer, Male, Invasive Breast Cancer
- Trial name
- NCT03387553
- Testing
- Dendritic Cell Vaccine (DC1), Neoadjuvant Chemotherapy, Curative Surgery
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer
Assessment of Invasive Mediastinal Staging in cN1 Lung Cancer.
This is a prospective non-randomized multicenter clinical trial performing endobronchial and esophageal ultrasound for mediastinal lymph node staging of operable and resectable cT1-T2-selectedT3 cN1 cM0 NSCLC.
- Trial name
- ASTER2 (NCT01456429)
- Testing
- Thoracic endosonography
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Renal Cell Carcinoma
Advantage of a Fast-recovery Protocol for Minimally Invasive Kidney Surgery
Shorten the time spent in the hospital (hospitalization duration) by optimizing the pre, per and postoperative care is of major medical and economic importance.
- Trial name
- RREIN (NCT04601129)
- Testing
- enhanced recovery after surgery program
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Lille
Urothelial Bladder Carcinoma, Bladder Carcinoma
Tumor Budding and T1 Substaging in Urothelial Bladder Cancer
Bladder cancer is a significant global and local health concern, and predicting how aggressive a patient's tumor will behave is critical for guiding treatment.
- Conditions
- Urothelial Bladder Carcinoma, Bladder Carcinoma, Non-Muscle-Invasive Bladder Cancer (NMIBC), Muscle-Invasive Bladder Cancer (MIBC)
- Trial name
- NCT07529639
- Volunteers
- 100 people
- Sponsor
- Assiut University
Invasive Breast Carcinoma
Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer
This trial studies the barriers associated with timely chemotherapy given after surgery (adjuvant) in patients with invasive breast cancer.
- Trial name
- NCT04087057
- Testing
- Interview, Medical Chart Review, Questionnaire
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)
To evaluate safety of 5 fraction accelerated partial brest irradiation in more convenient 5 fraction schedule.
- Trial name
- NCT01961531
- Testing
- Accuboost APBI
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Brown University
Non-Muscle Invasive Bladder Carcinoma
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
This phase IV trial studies whether there is a relationship between how a patient is positioned while receiving bacillus Calmette Guerin (BCG) within the bladder (intravesical) and how long BCG stays in the bladder (dwell time)…
- Trial name
- NCT07474519
- Testing
- Accelerometry, BCG Solution, Electronic Health Record Review
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Estrogen Receptor Positive, HER2/Neu Negative
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
This phase I/II trial studies side effects and best dose of copanlisib when given together with letrozole and palbociclib and to see how well they work in treating hormone receptor positive HER2 negative stage I-IV breast cancer.
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Multifocal Breast Carcinoma
- Trial name
- NCT03128619
- Testing
- Biopsy of Breast, Copanlisib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Non-muscle Invasive Bladder Cancer (NMIBC)
Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
A parallel group, open label, multi-centre, phase I/II marker-lesion study of intravesical or intravenous pembrolizumab in recurrent intermediate risk NMIBC.
- Trial name
- PemBla (NCT03167151)
- Testing
- Pembrolizumab
- Where
- 3 sites in United Kingdom
- Volunteers
- 6 people
- Sponsor
- University of Oxford
Breast Cancer
Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer
This phase II trial is studying how well cryoablation therapy works in treating patients with invasive ductal breast cancer. Cryoablation kills tumor cells by freezing them.
- Trial name
- NCT00723294
- Testing
- cryosurgery, therapeutic conventional surgery
- Where
- 16 sites in United States
- Volunteers
- 99 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Bladder Cancer, Muscle Invasive Bladder Cancer
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
This research study is studying the effects of adding a certain type of immunotherapy to standard bladder-directed radiation as a treatment for muscle-invasive urothelial carcinoma of the bladder.
- Trial name
- NCT03747419
- Testing
- Avelumab, Radiation
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Cervical Cancers, Vulvar Cancer
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
To evaluate the safety and immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years.
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT03676101
- Testing
- 9-valent HPV Recombinant Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Breast Cancer, Breast Cancer Stage I
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
This is a single institution phase II randomized study evaluating the potential benefits of a supplement, tart cherry juice at high- versus low-doses, to prevent taxane induced peripheral neuropathy in breast and ovarian cancer…
- Conditions
- Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
- Trial name
- NCT06268665
- Testing
- Tart Cherry Juice
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- University of California, Davis
Breast Cancer, Breast Neoplasms
Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study
There is no granular retrospective data on breast cancer in transgender and gender-diverse (TGD) persons from a contemporary and diverse American cohort.
- Conditions
- Breast Cancer, Breast Neoplasms, Breast Adenocarcinoma, Breast Cancer Stage
- Trial name
- NCT06234488
- Where
- 22 sites in United States
- Volunteers
- 125 people
- Sponsor
- Medical College of Wisconsin
Breast Cancer, Ductal Carcinoma in Situ
Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer
The purpose of this study is to examine the genetic material called microRNA of three types of specimens from women with breast cancer.
- Trial name
- NCT02127073
- Testing
- Intranasal Oxytocin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Montefiore Medical Center
Urinary Bladder Cancer
Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to determine if TAR-200, an investigational drug-delivery system is safe and tolerable in patients with recurrent low or intermediate risk non-muscle-invasive bladder cancer (NMIBC) between diagnosis…
- Trial name
- NCT02720367
- Testing
- Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
- Where
- 2 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Taris Biomedical LLC
Non-muscle Invasive Bladder Cancer
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
The purpose of this study is to test the safety of the study drug 2141-V11 in people whose NMIBC did not respond to standard treatment, and who will not have the standard surgical procedure to remove the bladder.
- Trial name
- NCT05126472
- Testing
- anti-CD40 antibody 2141-V11, Intravesical Gemcitabine, Intravesical Gemcitabine with anti-CD40 antibody 2141-V11
- Where
- 7 sites in United States
- Volunteers
- 115 people
- Sponsor
- Memorial Sloan Kettering Cancer Center